Enlivex Therapeutics Ltd.
| NASDAQ: ENLV | Healthcare / Biotechnology / Israel |
| 10.40 | -0.5700 | -5.20% | Vol 46.72K | 1Y Perf 100.48% |
| Apr 19th, 2021 12:25 DELAYED |
| BID | 10.37 | ASK | 10.43 | ||
| Open | 10.89 | Previous Close | 10.97 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | 33.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 217.61 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 163.90M | Earnings Rating | — | |
| Price Range Ratio 52W % | 23.73 | Earnings Date | 29th Apr 2021 |
Today's Price Range 10.3110.90 | 52W Range 4.4929.40 |
Summary:
Neutral
| Technical Indicators: | Buy |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.40% | ||
| 1 Month | -19.28% | ||
| 3 Months | 4.58% | ||
| 6 Months | -16.83% | ||
| 1 Year | 100.48% | ||
| 3 Years | -30.04% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -84.47 | |||
ROE last 12 Months | -41.66 | |||
ROA (5Y Avg) | -38.93 | |||
ROA last 12 Months | -33.40 | |||
ROC (5Y Avg) | -98.58 | |||
ROC last 12 Months | -42.66 | |||
Return on invested Capital Q | -6.56 | |||
Return on invested Capital Y | -94.83 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| 4.80 | ||||
| - | ||||
| - | ||||
| -12.00 | ||||
| -7.43 | ||||
| 4.80 | ||||
| 1.22 | ||||
| 52.73M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 6.60 | ||||
| 7.20 | ||||
| 0.02 | ||||
| 0.02 | ||||
| -108.10 | ||||
| Leverage Ratio | 1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2020 | -0.18 | -0.16 | 11.11 |
| Q02 2020 | -0.24 | -0.23 | 4.17 |
| Q01 2020 | -0.24 | -0.07 | 70.83 |
| Q04 2019 | - | -0.28 | - |
| Q03 2019 | - | -0.23 | - |
| Q02 2019 | - | -0.14 | - |
| Q04 2017 | - | -0.17 | - |
| Q03 2017 | - | -0.32 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 29th Apr 2021 |
| Estimated EPS Next Report | - |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 46.72K |
| Shares Outstanding | 15.76M |
| Trades Count | 507 |
| Dollar Volume | 3.87M |
| Avg. Volume | 406.64K |
| Avg. Weekly Volume | 88.53K |
| Avg. Monthly Volume | 109.73K |
| Avg. Quarterly Volume | 464.51K |
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) stock closed at 10.97 per share at the end of the most recent trading day (a -2.32% change compared to the prior day closing price) with a volume of 85.54K shares and market capitalization of 163.90M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Enlivex Therapeutics Ltd. CEO is Oren Hershkovitz.
The one-year performance of Enlivex Therapeutics Ltd. stock is 100.48%, while year-to-date (YTD) performance is 30.13%. ENLV stock has a five-year performance of %. Its 52-week range is between 4.49 and 29.4, which gives ENLV stock a 52-week price range ratio of 23.73%
Enlivex Therapeutics Ltd. currently has a PE ratio of -, a price-to-book (PB) ratio of 4.80, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -33.40%, a ROC of -42.66% and a ROE of -41.66%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Enlivex Therapeutics Ltd., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Enlivex Therapeutics Ltd.’s next earnings report date is 29th Apr 2021.
The consensus rating of Wall Street analysts for Enlivex Therapeutics Ltd. is Strong Buy (1), with a target price of $33, which is +217.61% compared to the current price. The earnings rating for Enlivex Therapeutics Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enlivex Therapeutics Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enlivex Therapeutics Ltd. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.28, ATR14 : 1.54, CCI20 : -52.89, Chaikin Money Flow : -0.13, MACD : -1.21, Money Flow Index : 46.95, ROC : 3.49, RSI : 37.58, STOCH (14,3) : 48.54, STOCH RSI : 0.37, UO : 53.40, Williams %R : -51.46), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enlivex Therapeutics Ltd. in the last 12-months were:
Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
CEO: Oren Hershkovitz
Telephone: +972 26208072
Address: 14 Einstein Street, Nes Ziona 7403618, , IL
Number of employees: 36
